Most previous studies that have performed immunohistochemical staining for HER2 in ovarian serous carcinoma showed rare positive HER2 expression, and aberrant HER2 activation in HGSOC has not yet been evaluated, particularly with respect to the potential application of HER2-targeted therapy [35,36,37,38]. Here, ERBB2 is linked to ovarian serous carcinoma.